CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 119 enrolled
Drug / intervention
azithromycin +2 moredrug
Likely dose
azithromycin 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02677701
NCT02677701Phase 4Completed
CompareCT.gov

TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin

Seattle Children's Hospital·interventional·Posted Feb 9, 2016·Updated Jun 28, 2021

In Brief

A Phase 4 clinical trial evaluating azithromycin, placebo (for azithromycin), and 1 other intervention for Cystic Fibrosis. Completed, enrolled 119 participants across 39 sites.

Detailed Summary

This is a study to examine the effect of combining chronic oral azithromycin with inhaled tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically infected with P. aeruginosa.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Cystic Fibrosis Foundation, CF Therapeutics Development Network Coordinating Center

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 9, 2016
Enrollment StartOct 21, 2016
Primary CompletionFeb 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.4 years ago

Interventions

azithromycindrug

500mg tablet over-encapsulated to match placebo

placebo (for azithromycin)drug

inhaled tobramycindrug

clinically prescribed inhaled tobramycin used by subjects participating in the study